Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03017573 |
Recruitment Status :
Recruiting
First Posted : January 11, 2017
Last Update Posted : April 11, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer Triple-Negative Breast Cancer Head and Neck Cancer Cervical Cancer | Procedure: Tumor biopsies / Tumor surgery Procedure: Blood withdrawal | Not Applicable |
Patients will have blood and +/- tumor samples at the following times :
-
if eligible for surgery :
- at surgery (blood + tumor and nodes)
- after surgery (blood)
- 6 months after surgery if non recurrence (Blood)
- before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes if possible)
- before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)
- at progression (blood + tumor biopsie and nodes if possible)
-
if eligible for neoadjuvant chemotherapy :
- before neoadjuvant therapy (blood + tumor biopsie and nodes)
- during neoadjuvant therapy (post cycle 1) (blood)
- at the time of surgery (blood + tumor and nodes)
- 6 months after surgery if non recurrence (Blood)
- before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes)
- before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)
- at progression (blood + tumor biopsie and nodes)
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 700 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) |
Actual Study Start Date : | January 6, 2017 |
Estimated Primary Completion Date : | August 2028 |
Estimated Study Completion Date : | January 6, 2031 |
Arm | Intervention/treatment |
---|---|
Experimental: Tumor and blood sampling
Patients will have a biopsy or a surgery and blood sampling at different time points.
|
Procedure: Tumor biopsies / Tumor surgery
Tumoral tissues samples must be collected at different times points :
OR
Procedure: Blood withdrawal Blood samples must be collected at different times points :
OR
|
- Correlation between tumor molecular/immunological profile and Baseline clinicobiological features [ Time Frame: up to 6 months ]
- Correlation between disease recurrence and molecular and/or immunological biomarkers [ Time Frame: up to 24 months ]
- Correlation between genomic alterations and immune parameters [ Time Frame: up to 24 months ]
- Correlation between mutations load and immune parameters [ Time Frame: up to 24 months ]
- Correlation between ctDNA levels, de novo mutations in ctDNA and immune [ Time Frame: up to 24 months ]
- For cervical cancer patient, correlation between ctDNA levels and kinetics, and prognosis, prediction of recurrence [ Time Frame: up to 24 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Tumor types :
- Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy
- Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy
- Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery
- Newly diagnosed treatment-naïve cervical cancer patients (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2).
- Male or female patients ≥ 18 years of age
- Signed informed consent
Exclusion Criteria:
- Male or female patients ≤18 years old
- Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Individually deprived of liberty or placed under the authority of a tutor
- Patients not affiliated to the Social Security System
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03017573
Contact: Anne-Sophie PLISSONNIER | 01 47 11 23 78 | drci.promotion@curie.fr |
France | |
Institut Bergonie | Not yet recruiting |
Bordeaux, France, 33076 | |
Contact: Adeline PETIT, MD A.Petit@.bordeaux.unicancer.fr | |
Principal Investigator: Adeline PETIT, MD | |
Centre Oscar Lambret | Recruiting |
Lille, France, 59000 | |
Contact: Camille PASQUESOONE, MD c.pasquesoone@o-lambret.fr | |
Principal Investigator: Camille PASQUESOONE, MD | |
Centre Leon Berard | Not yet recruiting |
Lyon, France, 69373 | |
Contact: Nicolas CHOPIN, MD | |
Contact nicolas.chopin@lyon.unicancer.fr | |
Principal Investigator: Nicolas CHOPIN, MD | |
Institut Curie | Recruiting |
Paris, France, 75005 | |
Contact: Christophe LE TOURNEAU, MD christophe.letourneau@curie.fr | |
Principal Investigator: Christophe LE TOURNEAU, MD | |
Institut Curie Hopital Rene Huguenin | Recruiting |
Saint-cloud, France, 92210 | |
Contact: Nicolas POUGET, MD nicolas.pouget@curie.fr | |
Principal Investigator: Nicolas POUGET, MD |
Principal Investigator: | Christophe LE TOURNEAU, Prof. | Institut Curie |
Responsible Party: | Institut Curie |
ClinicalTrials.gov Identifier: | NCT03017573 |
Other Study ID Numbers: |
IC 2016-03 |
First Posted: | January 11, 2017 Key Record Dates |
Last Update Posted: | April 11, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months. |
Access Criteria: | Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA). |
Immunological biomarkers molecular profil Circulating tumor DNA (ctDNA) |
Uterine Cervical Neoplasms Triple Negative Breast Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female |
Urogenital Neoplasms Genital Diseases Uterine Neoplasms Uterine Cervical Diseases Uterine Diseases Breast Neoplasms Breast Diseases Skin Diseases |